JPMorgan Chase & Co. raised its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 10.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,466,752 shares of the biopharmaceutical company’s stock after acquiring an additional 227,668 shares during the period. JPMorgan Chase & Co. owned approximately 7.45% of Bellicum Pharmaceuticals worth $28,811,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Teachers Advisors LLC increased its position in Bellicum Pharmaceuticals by 5.5% during the 4th quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 1,844 shares during the period. Wells Fargo & Company MN increased its position in Bellicum Pharmaceuticals by 91.0% during the 1st quarter. Wells Fargo & Company MN now owns 76,081 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 36,242 shares during the period. Bank of New York Mellon Corp increased its position in Bellicum Pharmaceuticals by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 935 shares during the period. Swiss National Bank increased its position in Bellicum Pharmaceuticals by 51.2% during the 1st quarter. Swiss National Bank now owns 44,300 shares of the biopharmaceutical company’s stock worth $547,000 after purchasing an additional 15,000 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Bellicum Pharmaceuticals by 29.6% during the 1st quarter. Ameriprise Financial Inc. now owns 192,501 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 43,955 shares during the period. 55.73% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts have issued reports on the company. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday. Jefferies Group LLC reiterated a “buy” rating and set a $16.00 target price on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Raymond James Financial, Inc. set a $18.00 target price on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Wells Fargo & Company reiterated an “outperform” rating and set a $31.00 target price on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $26.20.

TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/19/jpmorgan-chase-co-has-28-81-million-holdings-in-bellicum-pharmaceuticals-inc-blcm.html.

Bellicum Pharmaceuticals, Inc. (BLCM) opened at 12.73 on Tuesday. The firm’s 50-day moving average price is $9.55 and its 200 day moving average price is $11.70. Bellicum Pharmaceuticals, Inc. has a 52-week low of $7.41 and a 52-week high of $23.11. The firm’s market cap is $422.97 million.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period in the prior year, the firm posted ($0.61) EPS. On average, equities analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($3.02) earnings per share for the current year.

In other news, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total transaction of $169,469.98. Following the sale, the vice president now owns 14,314 shares of the company’s stock, valued at $175,489.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 24,260 shares of company stock worth $290,048. Corporate insiders own 23.30% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.